Recent Updates
Recently added Catalysts
ZLAB Positive Sentiment

Zai Lab Announces Participation in March Investor Conference

Key Takeaway: Zai Lab Limited announced its participation in the Leerink Partners Global Biopharma Conference on March 11, 2024. Senior management will present at the event, which will be available via live webcast. The company focuses on innovative biopharmaceutical solutions for various medical conditions, emphasizing its commitment to improving global health.
Price reaction · baseline $17.96 (2024-05-29 close) · hit pre-market · 24 other ZLAB headline(s) in the window, move may be shared
day 0 close · peak
+1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Zai Lab is actively participating in investor conferences, indicating strong engagement.
  • The company aims to address significant unmet medical needs, showcasing its commitment to innovation.
  • Live webcasts and archived presentations enhance transparency and investor access.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+104%
120-day peak, hindsight
Typical move
8.5%
average across 4 past catalysts
Cash runway
~164 mo
Low dilution risk
Lead asset
ZL-1211
Phase 1 · Advanced Solid Tumor

Full Press Release Details

SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 6, 2024– Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in March 2024:
Leerink Partners Global Biopharma Conference 2024 Presentation: Monday, March 11, 2024, 4:00 p.m. ETLocation: Fontainebleau, Miami BeachRoom: Glimmer 3
A live webcast of the presentation will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and an archived replay will be available for up to 90 days following the completion of the event.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.
For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306695050/en/
For more information:
Investor Relations: Christine Chiou / Lina Zhang+1 (917) 886-6929 / +86 136 8257 6943 christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com
Media: Shaun Maccoun / Xiaoyu Chen+1 (415) 317-7255 / +86 185 0015 5011 shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com
Source: Zai Lab Limited

Frequently Asked Questions

When is Zai Lab's investor conference presentation?

Zai Lab's presentation is scheduled for March 11, 2024, at 4:00 p.m. ET.

Where will the investor conference take place?

The conference will be held at Fontainebleau, Miami Beach.

Will the presentation be available online?

Yes, a live webcast will be available on Zai Lab's Investor Relations page.

What is Zai Lab's focus area?

Zai Lab focuses on innovative products for oncology, autoimmune disorders, and more.

Last updated: May 30, 2024